Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBIT Margin (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBIT Margin for 10 consecutive years, with 135.65% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 239.0% year-over-year to 135.65%, compared with a TTM value of 140.17% through Sep 2025, down 13400.0%, and an annual FY2024 reading of 271.46%, down 257381.0% over the prior year.
  • EBIT Margin was 135.65% for Q3 2025 at Spero Therapeutics, down from 17.22% in the prior quarter.
  • Across five years, EBIT Margin topped out at 146.04% in Q4 2022 and bottomed at 12229.55% in Q1 2022.
  • Average EBIT Margin over 5 years is 2007.86%, with a median of 360.18% recorded in 2021.
  • The sharpest move saw EBIT Margin skyrocketed 4687128bps in 2021, then plummeted -1196376bps in 2022.
  • Year by year, EBIT Margin stood at 178.1% in 2021, then skyrocketed by 182bps to 146.04% in 2022, then plummeted by -2232bps to 3113.49% in 2023, then skyrocketed by 91bps to 289.17% in 2024, then skyrocketed by 53bps to 135.65% in 2025.
  • Business Quant data shows EBIT Margin for SPRO at 135.65% in Q3 2025, 17.22% in Q2 2025, and 250.78% in Q1 2025.